Patents by Inventor Brian S. J. Blagg

Brian S. J. Blagg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GRP94 selective inhibitors and uses thereof
    Patent number: 11939291
    Abstract: The present technology provides compounds according to Formula I or Formula III as well as compositions including such compounds useful for the treatment of metastatic cancer and/or glaucoma.
    Type: Grant
    Filed: April 9, 2021
    Date of Patent: March 26, 2024
    Assignees: University of Kansas, University of South Florida
    Inventors: Sanket Jaiprakash Mishra, Brian S. J. Blagg, Chad Anthony Dickey
  • Biphenyl amides with modified ether groups as HSP90 inhibitors and HSP70 inducers
    Patent number: 11708319
    Abstract: Provided herein are compounds of the formulas: wherein: n, X2, R3, R3?, R4, R4?, R5, R5?, R6, and R6? are as defined herein. Pharmaceutical compositions of the compounds are also provided. In some aspects, these compounds may be used for the treatment of diseases, including diabetic peripheral neuropathy or cancer.
    Type: Grant
    Filed: July 14, 2021
    Date of Patent: July 25, 2023
    Assignee: UNIVERSITY OF KANSAS
    Inventors: Brian S. J. Blagg, Rick T. Dobrowsky, Mercy Anyika
  • C-TERMINAL HSP90 INHIBITORS
    Publication number: 20230102047
    Abstract: Hsp90 C-terminal inhibitors and pharmaceutical compositions containing such compounds are provided. The compounds of the disclosure are useful for the treatment and/or prevention of neurodegenerative disorders such as diabetic peripheral neuropathy.
    Type: Application
    Filed: July 12, 2022
    Publication date: March 30, 2023
    Inventors: Brian S.J. BLAGG, Bhaskar Reddy KUSUMA, Teather SUNDSTROM
  • C-terminal Hsp90 inhibitors
    Patent number: 11390640
    Abstract: Hsp90 C-terminal inhibitors and pharmaceutical compositions containing such compounds are provided. The compounds of the disclosure are useful for the treatment and/or prevention of neurodegenerative disorders such as diabetic peripheral neuropathy.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: July 19, 2022
    Assignee: UNIVERSITY OF KANSAS
    Inventors: Brian S. J. Blagg, Bhaskar Reddy Kusuma, Teather Sundstrom
  • BIPHENYL AMIDES WITH MODIFIED ETHER GROUPS AS HSP90 INHIBITORS AND HSP70 INDUCERS
    Publication number: 20220041543
    Abstract: Provided herein are compounds of the formulas: wherein: n, X2, R3, R3?, R4, R4?, R5, R5?, R6, and R6? are as defined herein. Pharmaceutical compositions of the compounds are also provided. In some aspects, these compounds may be used for the treatment of diseases, including diabetic peripheral neuropathy or cancer.
    Type: Application
    Filed: July 14, 2021
    Publication date: February 10, 2022
    Inventors: Brian S.J. BLAGG, Rick T. DOBROWSKY, Mercy ANYIKA
  • GRP94 SELECTIVE INHIBITORS AND USES THEREOF
    Publication number: 20220024869
    Abstract: The present technology provides compounds according to Formula I or Formula III as well as compositions including such compounds useful for the treatment of metastatic cancer and/or glaucoma.
    Type: Application
    Filed: April 9, 2021
    Publication date: January 27, 2022
    Inventors: Sanket Jaiprakash Mishra, Brian S.J. Blagg, Chad Anthony Dickey
  • SECOND GENERATION GRP94-SELECTIVE INHIBITORS
    Publication number: 20210300872
    Abstract: The present technology provides compounds selective for the Grp94 isoform, as well as compositions including such compounds, that are useful for treatment of multiple myeloma, melanoma, lung cancer, hepatocellular carcinoma, breast cancer, prostate cancer, and/or glaucoma. Methods using the compound are also provided.
    Type: Application
    Filed: June 7, 2021
    Publication date: September 30, 2021
    Inventors: Brian S.J. Blagg, Vincent Matthew Crowley
  • Biphenyl amides with modified ether groups as Hsp90 inhibitors and Hsp70 inducers
    Patent number: 11098008
    Abstract: Provided herein are compounds of the formulas: wherein: n, X2, R3, R3?, R4, R4?, R5, R5?, R6, and R6? are as defined herein. Pharmaceutical compositions of the compounds are also provided. In some aspects, these compounds may be used for the treatment of diseases, including diabetic peripheral neuropathy or cancer.
    Type: Grant
    Filed: January 29, 2020
    Date of Patent: August 24, 2021
    Assignee: UNIVERSITY OF KANSAS
    Inventors: Brian S. J. Blagg, Rick T. Dobrowsky, Mercy Anyika
  • C-TERMINAL HSP90 INHIBITORS
    Publication number: 20210188891
    Abstract: Hsp90 C-terminal inhibitors and pharmaceutical compositions containing such compounds are provided. The compounds of the disclosure are useful for the treatment and/or prevention of neurodegenerative disorders such as diabetic peripheral neuropathy.
    Type: Application
    Filed: December 4, 2020
    Publication date: June 24, 2021
    Inventors: Brian S.J. BLAGG, Bhaskar Reddy KUSUMA, Teather SUNDSTROM
  • Second generation GRP94-selective inhibitors
    Patent number: 11028041
    Abstract: The present technology provides compounds selective for the Grp94 isoform, as well as compositions including such compounds, that are useful for treatment of multiple myeloma, melanoma, lung cancer, hepatocellular carcinoma, breast cancer, prostate cancer, and/or glaucoma. Methods using the compounds are also provided.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: June 8, 2021
    Assignee: University of Kansas
    Inventors: Brian S. J. Blagg, Vincent Matthew Crowley
  • Grp94 selective inhibitors and uses thereof
    Patent number: 10975030
    Abstract: The present technology provides compounds according to Formula I or Formula III as well as compositions including such compounds useful for the treatment of metastatic cancer and/or glaucoma.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: April 13, 2021
    Assignees: University of Kansas, University of South Florida
    Inventors: Sanket Jaiprakash Mishra, Brian S. J. Blagg, Chad Anthony Dickey
  • HSP90B N-terminal isoform-selective inhibitors
    Patent number: 10927076
    Abstract: The present technology provides compounds according to Formula (I) as well as compositions including such compounds useful for the treatment of cancers such as non-small cell lung cancer, bladder cancer, or colon cancer.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: February 23, 2021
    Assignee: University of Kansas
    Inventors: Brian S. J. Blagg, Caitlin Nicole Kent, Anuj Khandelwal, Sanket Jaiprakash Mishra
  • GRP94 INHIBITORS TO TREAT STEROID-INDUCED OCULAR HYPERTENSIONS AND GLAUCOMAS
    Publication number: 20210030719
    Abstract: A method and composition for preventing, reducing, or treating steroid-induced ocular hypertension and steroid-induced glaucoma using a selective Grp94 inhibitor is presented. The Grp94-selective inhibitor can include methyl 2-(2-(1(4-bromobenzyl)-1H-imidazol-2-yl)ethyl)-3-chloro-4,6-dihydroxybenzoate (4-Br—BnIm) or a derivative thereof. The Grp94-selective inhibitor can be administered prior to, during, or after administration of a steroid to the patient.
    Type: Application
    Filed: February 22, 2019
    Publication date: February 4, 2021
    Inventors: Chad A. DICKEY (Deceased), John KOREN, Laura J. BLAIR, Brian S.J. BLAGG, Ricardo A. CORDOVA, Zheying SUN
  • C-terminal Hsp90 inhibitors
    Patent number: 10882881
    Abstract: Hsp90 C-terminal inhibitors and pharmaceutical compositions containing such compounds are provided. The compounds of the disclosure are useful for the treatment and/or prevention of neurodegenerative disorders such as diabetic peripheral neuropathy.
    Type: Grant
    Filed: February 5, 2020
    Date of Patent: January 5, 2021
    Assignee: UNIVERSITY OF KANSAS
    Inventors: Brian S. J. Blagg, Bhaskar Reddy Kusuma, Teather Sundstrom
  • C-TERMINAL HSP90 INHIBITORS
    Publication number: 20200283465
    Abstract: Hsp90 C-terminal inhibitors and pharmaceutical compositions containing such compounds are provided. The compounds of the disclosure are useful for the treatment and/or prevention of neurodegenerative disorders such as diabetic peripheral neuropathy.
    Type: Application
    Filed: February 5, 2020
    Publication date: September 10, 2020
    Inventors: Brian S.J. BLAGG, Bhaskar Reddy KUSUMA, Teather SUNDSTROM
  • BIPHENYL AMIDES WITH MODIFIED ETHER GROUPS AS HSP90 INHIBITORS AND HSP70 INDUCERS
    Publication number: 20200270201
    Abstract: Provided herein are compounds of the formulas: wherein: n, X2, R3, R3?, R4, R4?, R5, R5?, R6, and R6? are as defined herein. Pharmaceutical compositions of the compounds are also provided. In some aspects, these compounds may be used for the treatment of diseases, including diabetic peripheral neuropathy or cancer.
    Type: Application
    Filed: January 29, 2020
    Publication date: August 27, 2020
    Inventors: Brian S.J. BLAGG, Rick T. DOBROWSKY, Mercy ANYIKA
  • Coumarin based HSP90 inhibitors with urea and ether substituents
    Patent number: 10745386
    Abstract: Compounds of the formulas: wherein: R1-R4, X1, Y1, and A are as defined herein are provided. Pharmaceutical compositions of the compounds are also provided. In some aspects, these compounds are useful for the treatment of a disease or disorder. In some embodiments, the disease or disorder is a proliferative disease such as cancer.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: August 18, 2020
    Assignee: UNIVERSITY OF KANSAS
    Inventors: Brian S. J. Blagg, Huiping Zhao
  • Biphenylamide derivative Hsp90 inhibitors
    Patent number: 10689344
    Abstract: Compounds of the formulas are provided: wherein variables Y1-Y5, X1-X5, A1-A4, X, y, n1, n2, and R1-R15 are as defined herein. Pharmaceutical compositions of the compounds are also provided. In some aspects, these compounds are useful for the treatment of a disease or disorder, including, for example, a proliferative disease, such as cancer.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: June 23, 2020
    Assignee: UNIVERSITY OF KANSAS
    Inventors: Brian S. J. Blagg, Huiping Zhao
  • SECOND GENERATION GRP94-SELECTIVE INHIBITORS
    Publication number: 20200190017
    Abstract: The present technology provides compounds selective for the Grp94 isoform, as well as compositions including such compounds, that are useful for treatment of multiple myeloma, melanoma, lung cancer, hepatocellular carcinoma, breast cancer, prostate cancer, and/or glaucoma. Methods using the compounds are also provided.
    Type: Application
    Filed: August 23, 2018
    Publication date: June 18, 2020
    Inventors: Brian S.J. Blagg, Vincent Matthew Crowley
  • Biphenyl amides with modified ether groups as HSP90 inhibitors and HSP70 inducers
    Patent number: 10590065
    Abstract: Provided herein are compounds of the formulas: (I) wherein: n, X2, R3, R3?, R4, R4?, R5, R5?, R6, and R6? are as defined herein. Pharmaceutical compositions of the compounds are also provided. In some aspects, these compounds may be used for the treatment of diseases, including diabetic peripheral neuropathy or cancer.
    Type: Grant
    Filed: June 24, 2015
    Date of Patent: March 17, 2020
    Assignee: UNIVERSITY OF KANSAS
    Inventors: Brian S. J. Blagg, Rick T. Dobrowsky, Mercy Anyika